Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

AEGR 25.42 -0.52 (-2.00%)
price chart
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Aegerion Pharma Buys Drug From AstraZeneca for $325M  Mergers & Acquisitions - The Middle Market
Related articles »  
Aegerion Pharmaceuticals, Inc. Soars After Sarissa Capital Discloses Stake
The shares of Aegerion Pharmaceuticals surged after Sarissa Capital Management disclosed its stake in the company. The stock was trading at $25.70 per share, up by more than 8% to $25.87 per share at the time of this writing around 2:33 in the ...
Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals  Benzinga
Form SC 13D Aegerion Pharmaceuticals Filed by: Sarissa Capital Management LP  StreetInsider.com
Aegerion Pharmaceuticals, Inc. (AEGR), Joint Corp (JYNT), Trillium ...
At Insider Monkey, we track over 700 of the top hedge funds in the world, following and reporting on their latest moves disclosed through filings with the Securities and Exchange Commission on a daily basis.
Aegerion Pharmaceuticals Observes Rare Disease Day
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare ...
Stocks With Perfect Match- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) [Trend Analysis] reported that the firm expected to host a conference call and live audio webcast at 5:00 p.m.
Aegerion Pharmaceuticals (AEGR) Stock Downgraded Today at Jefferies
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared ...
Aegerion Falls On Disappointing Earnings  Bidness ETC
Aegerion Pharmaceuticals (AEGR) Earnings Crushes Shares  Wall Street Pit
Related articles »  
Townsquare Media Inc, Aegerion Pharmaceuticals, Inc.: Tricadia Capital ...
Another filing revealed that Alex Denner's Sarissa Capital Management has entered a new position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The fund's new holding consists of around 1.6 million common shares, which amounts to 5.76% of the ...
Aegerion Pharmaceuticals, Inc. (AEGR) & The GEO Group Inc (GEO): Scopia ...
Scopia Capital Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has acquired 4.2 million shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a $900 million market cap biopharmaceutical ...
Why Aegerion Pharmaceuticals (AEGR) Stock Is Down Today  TheStreet.com
Related articles »  
Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes ...
Aegerion Pharmaceuticals, Inc. AEGR, -2.00% today announced the pricing of its offering of $300 million aggregate principal amount of 2.00% convertible senior notes due 2019 to persons that they reasonably believe to be qualified institutional buyers ...
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds' bullishness. Not only did Steve Cohen's Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich's ...
Related articles »